OpGen reports FY2022 revenue $2.6M, down 40% YoY; guides FY2023 revenue $4-5M

CapForce Inc.

FY2022 total revenue ~$2.6M vs $4.3M in 2021; Q4 revenue $722K, down 48% YoY but up 61% QoQ.
Operating expenses $37.2M for FY2022, including $12.3M goodwill and IPR&D impairment charges.
Cash and equivalents $7.4M at Dec 31, 2022, down from $36.1M; recent $7.5M public offering closed.
FY2023 guidance: revenue $4-5M; net cash consumption $4.5-5M per quarter; EIB loan restructuring discussions for EUR 3M due June 2023.
Unyvero UTI FDA De Novo submission expected early Q2 2023; ARESiss first US commercial orders received.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CapForce Inc. reported full year ended December 31, 2022 results: revenue approximately $2.6 million. Guidance reaffirmed.

Period: full year ended December 31, 2022
Revenue: approximately $2.6 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Its total revenue for 2022 was approximately $2.6 million which was in line with the Company's most recent guidance.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CapForce Inc. reported the fourth quarter of 2022 results: revenue approximately $722 thousand.

Period: the fourth quarter of 2022
Revenue: approximately $722 thousand
Result: reported results

Exact text from the filing

OpGen's revenue for the fourth quarter of 2022 was approximately $722 thousand.

View on SEC.gov

Browse all earnings releases →

CapForce Inc. filing history →

Source: SEC EDGAR

accession 0001079973-23-000394

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.